A newly identified hormone called asprosin may help doctors catch dangerous liver disease years before serious damage occurs. Researchers found that this hormone, produced by fat tissue, acts as a protective guardian in early-stage fatty liver disease but becomes a red flag for advanced disease as the condition worsens. This discovery could transform how doctors screen patients at risk for liver failure and cancer .

Around 30% of the world's population suffers from metabolic dysfunction-associated steatotic liver disease, or MASLD, a condition where excess fat accumulates in the liver and exceeds 5% of the organ's total weight . Previously called non-alcoholic fatty liver disease, MASLD is the leading cause of liver-related death in humans and often develops silently over many years without any noticeable symptoms.

What Happens When Fatty Liver Disease Progresses?

The real danger emerges when MASLD transforms into metabolic dysfunction-associated steatohepatitis, or MASH, an inflammatory state where the liver becomes damaged. At this stage, the organ can develop scarring, fail completely, or even develop hepatocellular carcinoma, a type of liver cancer. These complications can be fatal . People with obesity, insulin resistance, and type 2 diabetes face particularly high risk of developing this disease.

Researchers at the Salvador Zubirán National Institute of Health Sciences and Nutrition in Mexico conducted a groundbreaking study published in the Journal of Lipid Research to understand asprosin's role in this disease progression. They treated liver cells and mice with obesity at different disease stages with asprosin and observed how the hormone affected fat metabolism in the liver .

How Does Asprosin Change as Disease Progresses?

The findings revealed asprosin's dual nature. At early stages of obesity, asprosin elevated the expression of genes and proteins involved in breaking down fat, preventing fat from accumulating in the liver. This protective effect helped prevent disease progression. However, as obesity advanced and the disease worsened, this protective effect disappeared entirely. Instead, higher levels of asprosin indicated severe disease .

To confirm these laboratory findings in real patients, researchers measured asprosin levels in individuals who underwent FibroScan imaging, a diagnostic ultrasound technique that measures liver fat accumulation and stiffness. They discovered that individuals with more advanced disease, evident from increased liver fat and stiffness, had significantly elevated asprosin levels compared to healthy individuals .

Ways to Monitor Liver Health and Catch Disease Early

• Asprosin Testing: Healthcare providers may soon incorporate asprosin level measurements into routine screening for patients at risk of MASLD, using blood tests to detect disease progression before symptoms appear.
• FibroScan Imaging: This non-invasive ultrasound technique measures both liver fat content and stiffness, helping doctors assess disease severity without requiring a liver biopsy.
• Regular Liver Enzyme Screening: Patients with obesity, diabetes, or insulin resistance should have periodic liver function tests to catch early signs of fatty liver disease.

The implications are significant. Asprosin can now serve as a biomarker in healthcare settings to detect deteriorating liver health and disease progression in patients with MASLD . A biomarker is a measurable indicator of disease that doctors can track over time.

Why This Discovery Matters for Young People with Diabetes

The urgency of early detection is particularly acute in younger patients. Research published in BMC Endocrine Disorders examined 51 young people with type 2 diabetes who had elevated liver enzymes and liver biopsies between 2010 and 2023. The study found that 41% of these young patients already had stage 3 or 4 liver fibrosis, the most advanced stages of scarring .

Researchers identified another liver enzyme called gamma glutamyl transferase, or GGT, as a useful screening tool. For every 10 U/L increase in GGT levels, the odds of having advanced liver fibrosis increased by 20% in young people with type 2 diabetes . This finding suggests that pediatricians and primary care providers should pay closer attention to GGT levels when screening young diabetic patients for liver disease.

The combination of these discoveries offers hope for millions of people at risk. Rather than waiting for symptoms to appear or disease to advance to dangerous stages, doctors may soon have multiple tools to catch liver disease early. Asprosin levels could serve as an early warning system, while GGT testing provides an additional screening marker for high-risk groups like young people with diabetes. Together, these biomarkers represent a shift toward preventive medicine, where intervention can occur before irreversible damage develops.